口服长春瑞滨在中国治疗晚期非小细胞肺癌和转移性乳腺癌的费用研究  

A Time and Motion Cost Analysis of Oral Vinorelbine for the Treatment of Advanced Non-small Cell Lung Cancer and Metastatic Breast Cancer in China

作　　者：张蕾 郑红淑 刘晶[3] 宣建伟 刘雪松 

机构地区：[1]上海盛特尼医药科技有限公司,上海200030 [2]皮尔法伯(上海)管理咨询有限公司,上海200070 [3]中山大学,广州510275

出　　处：《中国医疗保险》2016年第10期54-58,共5页China Health Insurance

摘　　要：目的 :比较口服化疗药长春瑞滨和静脉化疗药在中国治疗晚期非小细胞肺癌和转移性乳腺癌与给药途径有关的医疗资源的使用情况。方法 :通过时间-效益研究来确定治疗晚期非小细胞肺癌和转移性乳腺癌的与给药途径有关的费用。结果 :口服长春瑞滨的一个治疗疗程的医疗资源平均总花费是1,809.24元(药品价格除外),静脉化疗药的一个治疗疗程的医疗资源平均总花费是16,241.4元(药品价格除外)。结论 :口服化疗药长春瑞滨与静脉化疗方案相比,能够显著降低与给药有关的医护人员的时间、患者生产力的损失以及获得药物的整体系统医疗资源成本。Objective The study aimed to quantify resource use associated with oral chemotherapies vinorelbine versus other selected IV chemotherapies in the treatment of advanced NSCLC and MBC in Chinese setting. Method A time and motion study was conducted to identify the drug administration related resource use and cost of the oral vinorelbine and IV chemotherapies in the treatment of advanced NSCLC and MBC. Result The total 4-cycle medical cost for single-agent oral vinorelbine therapy excluding drug cost is ￥1,809.24, the total 4-cycle medical cost for IV single-agent treatment excluding drug costs is ￥16,241.4. Conclusion Oral vinorelbine significantly reduces drug administration related healthcare provider＇s time, patient productivity loss and overall drug delivery costs compared with an IV chemotherapy regimen.

关 键 词：口服诺维本 时间—效益研究 费用 

分 类 号：R737.9[医药卫生—肿瘤] R734.2[医药卫生—临床医学] R197.3